





**Part 1 - Diagnostic approach (Q27 - Q39)**














**Other:** small bowel series; ultrasound; either MRe or capsule




















**Other:** not yearly; every 2-3 years; case by case; depending on age and the endoscopic activity; at transition




**Other:** not yearly; every 2-5 years; depending on disease activity and histological findings; at transition




**Part 2 - Therapeutic approach (Q40 - Q89)**







**Other:** not available in our country; tofacitinib; natalizumab; abatacept




**Other:** as for CD




**Legend (y axis from top):** yes, but only in anti-TNF naiive; yes, including switch; not, but biosimilars are approved in my country; biosimilars are not approved in my country




**Legend (y axis from top):** yes, but only in anti-TNF naiive; yes, including switch; not, but biosimilars are approved in my country; biosimilars are not approved in my country








**Comments:** stem cell transplant; faecal transplant; immunotherapy; leukocyte apheresis; boswellia; worms; antibiotics; tacrolimus





**No relevant comments under "other"**





































**Other:** anti-TNF for high-risk CD; no preference; AZA+steroids+EEN




















**Other:** AZA/6-MP in girls; MTX in boys




**Other:** N/A as top down; MTX,IFX,ADA; allopurinol and monoclonals; enteral nutrition; depending on side effects and/or severity; **Legend (y axis from top):** other IMM; IFX; ADA; either of each (regarded as equally efficacious); I don´t know; other (please specify)




**Other:** N/A as top down; ADA or IFX; allopurinol and monoclonals; enteral nutrition; case dependent






**Legend (y axis from top):** in a minority / in none of the patients; I do not know; in a majority / in all of the patients (please give the interval)


**Interval:** 3-6 months; 4 months; 4-6 months; 6-9 months; 3-9 months; 6-12 months; 1 year; 2 years






**Legend (y axis from top):** in a minority / in none of the patients; I do not know; in a majority / in all of the patients (please give the interval)


**Interval:** 3-6 months; 4 months; 4-6 months; 6-9 months; 3-9 months; 6-12 months; 1 year; 2 years




**Legend (y axis from top):** IFX; ADA; either of each (regarded as equally efficacious); I do not know





**Legend (y axis from top):** IFX; ADA; either of each (regarded as equally efficacious); I do not know





























**Other:** tacrolimus; cyclosporine A (CSA); mycophenolate mofetil; either IFX or CSA (individual decision)







**Other:** monitor with post-operative colonoscopy and faecal calprotectin; 3 months metronidazole, AZA, PEN; IFX or AZA; 6-MP



**Other:** same as above (Q 86); depending on localisation of the disease



**Legend (y axis from top):** in all patients in regular intervals; in high-risk patients in regular intervals; in all patients based on clinical/laboratory markers (e.g. calprotectin); in high-risk patients based on clinical/laboratory markers (e.g. calprotectin); no; I do not know



**Other:** colectomy and ileostomy and ileonal J pouch at a second stage; temporary stoma + defunction as first step; based on interdisciplinary approach individually tailored to the patient